Short term effects of levothyroxine treatment in thyroid multinodular disease

The levothyroxine suppressive efficacy in benign thyroid nodules treatment is well described in uninodular non-toxic goiter, whereas only few controlled trials enrolled patients with multinodular disease. The aim of the present study is to evaluate the short term effects of levothyroxine treatment i...

Full description

Saved in:
Bibliographic Details
Published in:ENDOCRINE JOURNAL 2010, Vol.57(9), pp.803-809
Main Authors: Cesareo, Roberto, Iozzino, Mario, Isgrò, Maria Antonietta, Annunziata, Francesca, Stasio, Enrico Di
Format: Article
Language:English
Subjects:
Adult
Female
Goiter, Nodular - diagnostic imaging
Goiter, Nodular - drug therapy
Goiter, Nodular - pathology
Humans
Levothyroxine therapy
Middle Aged
Multinodular goiter
Pre-menopausal women
Premenopause
Thyroid
Thyroid Gland - diagnostic imaging
Thyroid Gland - pathology
Thyrotropin
Thyroxine - blood
Thyroxine - therapeutic use
Triiodothyronine - blood
Ultrasonography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The levothyroxine suppressive efficacy in benign thyroid nodules treatment is well described in uninodular non-toxic goiter, whereas only few controlled trials enrolled patients with multinodular disease. The aim of the present study is to evaluate the short term effects of levothyroxine treatment in never treated, pre-menopausal women affected by thyroid multinodular disease. Seventy-one pre-menopausal women with thyroid multinodular disease, still presenting normal TSH levels, from Latina area were randomly assigned to a levothyroxine treated or control group. Biochemical and ultrasonography evaluations of thyroid were monitored at the enrolment and after 6, 12 and 24 months of treatment. In the levothyroxine treated group, after 1 year of treatment, thyroid and dominant nodule volume and number of nodules >0.5 mL significantly decreased from a median of 12.0 to 9.8 mL (p
ISSN:0918-8959
1348-4540
DOI:10.1507/endocrj.K10E-144